Medicinova Nachrichten und Aktivitäten
Präsenz
Medicinova ist ein Unternehmen, das unter dem Börsenticker MNOV (US) gelistet ist.
Führungskräfte
Siehe das Organigramm mit seine 7 wichtigsten Führungskräfte
Die meist gesuchten Biographien bei Medicinova
- Yuichi Iwaki, Director, President and Chief Executive Officer
- Hideki Nagao, Director
- Jeff Himawan, Chairman of the Board
Eine Benachrichtigung erstellen
um Veränderungen bei Führungskräften von Medicinova nachzuverfolgen.
Biotechnologie
Medicinova hat 2.350 Konkurrenten , einschließlich Eurofins (Luxemburg), Lonza (Schweiz) und Johnson & Johnson Innovative Medicine DIA (USA).
Popular M&A news in Biotechnologie
- Transcarent and Accolade have merged (veröffentlicht am 9, April 2025)..
- Kashiv BioSciences hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 7, April 2025).
- Atsena Therapeutics hat gerade eine Spendenaktion von 150 Millionen Dollar angekündigt. (veröffentlicht am 4, April 2025).
Andere vorgeschlagene Kontakte der Biotechnologie branche
Nachrichten
Neueste Pressemitteilungen nach Medicinova
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada | MediciNova, Inc.
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria | MediciNova, Inc.
- MediciNova Receives Gene Therapy Milestone Payment | MediciNova, Inc.
- MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe | MediciNova, Inc.
- MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe | MediciNova, Inc.
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology | MediciNova, Inc.
- MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe | MediciNova, Inc.
- MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting | MediciNova, Inc.
- View more press releases Close
Social media about Medicinova
- Medicinova auf Wikipedia, Google News & Yahoo Finance
- Medicinova auf LinkedIn, Twitter & YouTube
